Published in Biosci Rep on March 23, 2017
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 19.26
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr (2005) 6.67
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol (2000) 2.97
Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol (2003) 2.46
Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One (2013) 2.02
Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) (2011) 2.00
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.89
Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (1997) 1.88
IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol (2011) 1.72
Plasma adiponectin and gastric cancer. Clin Cancer Res (2005) 1.62
Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut (2006) 1.58
Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.56
Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res (2011) 1.38
Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol (2011) 1.30
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol (2010) 1.26
A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer (2011) 1.25
Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer (2006) 1.22
Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.17
A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut (2011) 1.14
The metabolic syndrome: common origins of a multifactorial disorder. Postgrad Med J (2009) 1.13
Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut (2011) 1.13
Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev (2008) 1.12
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut (2010) 1.04
The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl (2003) 1.04
Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncol (2015) 1.02
Regional adipocity in man. J Endocrinol (1997) 1.00
Comparison of various surrogate obesity indicators as predictors of cardiovascular mortality in four European populations. Eur J Clin Nutr (2013) 0.97
Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer (2014) 0.95
Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology (2013) 0.94
Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. Int J Cancer (2014) 0.94
Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol (2007) 0.93
Trajectory of body shape across the lifespan and cancer risk. Int J Cancer (2016) 0.93
Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric Cancer (2014) 0.92
The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol (2014) 0.90
General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2015) 0.89
Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies. Sci Rep (2014) 0.88
Metabolic syndrome and esophageal and gastric cancer. Cancer Causes Control (2015) 0.88
IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology (2003) 0.87
Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg (2012) 0.85
The rapid rise in gastroesophageal junction tumors: is inflammation of the gastric cardia the underwater iceberg? Gastroenterology (2013) 0.84
Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer Causes Control (2012) 0.84
The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2015) 0.82
Abdominal adiposity through adipocyte secretion products, a risk factor for endometrial cancer. Gynecol Endocrinol (2013) 0.82
Obesity: Screening for the evident in obesity. Nat Rev Endocrinol (2012) 0.80
Prospective cohort study of general and central obesity, weight change trajectory and risk of major cancers among Chinese women. Int J Cancer (2016) 0.78
Central obesity and risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective studies. Obes Rev (2016) 0.78
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc (2016) 0.77